# Roswell Park Comprehensive Cancer Center Section 203 Budget Filing Fiscal Year 2023 - 2024

**PROPOSED** 



**January 31, 2023** 

#### Public Authority Relationship with Unit of Government

203.6(a)

#### **Roswell Park Comprehensive Cancer Center**


The institute was founded in 1898 and became a State Institute in 1911. In 1971, it was one of the first three institutions certified as a comprehensive cancer center by the National Cancer Institute. As such, it is committed to combat cancer through basic research, clinical research and treatment, and professional and public education. Presently, there are 53 such centers designated in the United States. The institute is a 142 licensed bed facility and an ambulatory care center containing 15 multidisciplinary care centers with a staff of over 3,500 members, including clinical staff physicians, residents, fellows, and research staff. The primary physical plant covers several city blocks in downtown Buffalo.

The operation of the Institute transferred from the New York Department of Health to the RPCI Corporation on January 1, 1999. In order to meet the demands of the changing health care marketplace and to promote the strengths and capabilities of the Institute, Chapter 5 of the Laws of 1997 added a new Title 4 to Article 10-c of the Public Authorities Law authorizing the RPCI Corporation. This legislative authorization was intended to change the Institute's governance structure to afford it market and managerial flexibility. Among the special powers granted by the legislation to the Corporation were the powers to contract with the State to operate, manage, superintend and control the Institute, and to establish, collect, and adjust fees, rental and other charges in connection with the operation of the Institute.

Pursuant to subdivision 2 of Section 403 of the Public Health Law, added by such chapter, the Department of Health, acting on behalf of the State, entered into an Operating Agreement with RPCI Corporation pursuant to which operating responsibility for the Institute was transferred to RPCI Corporation effective January 1, 1999, and giving RPCI Corporation substantial independence operating the Institute, including the power to establish operating budgets, to establish and implement strategic business plans, to create subsidiary and affiliated entities, to enter into affiliations and alliances with other health care providers and to establish, collect and adjust fees, rentals and other charges in connection with the operation of the Institute. Revenues generated by the Corporation as a result of operating the Institute are considered to be revenues of the State for the purpose of its bond payment, and are required to be deposited into the Roswell Park Cancer Institute Debt Service Account of the Health Income Fund for payment of debt service on the Bonds. The Department of Health retains responsibility for paying debt service on the Bonds. After allowing for accumulation of a debt service reserve for the Institute, the remaining revenues are transferred to Roswell Park Cancer Institute Income Account of the Health Income Fund. After allowing for a balance for refunds these revenues are, in turn, transferred to RPCI Corporation.

RPCI Corporation's responsibility is to ensure the fiscal and programmatic integrity of the facility. To achieve this objective, the Corporation has updated the strategic plan for the Institute which includes major programmatic and scientific, as well as, fiscal goals. Some of the key goals include the recruitment of top tier clinical and scientific talent; developing a methodology to monitor the effectiveness of programs and faculty; enhancing financial viability through revenue and expense controls; building a strong and profitable biotechnology transfer program in collaboration with peer facilities; emphasis on clinical and translational research; as well as developing and implementing new clinical trials and establishing a cancer disease management and clinical outcomes program.

The Institute is a formally designated unit of the Graduate School of the University of New York at Buffalo and has numerous affiliation agreements with other educational institutions and hospitals. Training provided by the Institute under these arrangements includes medical, nursing and medical research.



#### **Budget Assumptions**

- Revenue assumptions:
  - Base volumes

Admits 7.3%Days 12.0%

- Outpatient Visits 6.8%
- Rate assumptions
  - Payer rates as negotiated
  - Governmental payer rates per regulations
- Sources of revenues:
  - Includes private and governmental contracts, grants and donations, and funding from New York State
- Staffing:
  - At current levels, adjusted for productivity standards, new initiatives, strategic research initiatives and infrastructure
- Future collective bargaining costs:
  - Bargaining unit increases for FY24 include Step and COLA per negotiated contracts

#### Inflation:

- Salaries Steps and COLA factored in as previously noted
- Fringe Benefits increased consistent with salaries
- Pharmaceuticals (inflation, utilization, new therapies) = 12%
- Medical supplies, office supplies, purchased services = 4.0%; Blood supplies = 4.5%

#### Programmatic Goals:

- Continued expansion of local community presence
- Implementation of Roswell Park's strategic plan, including
  - Expand adoptive cellular therapy as new treatments options become available for patients
  - Expand access to Roswell Park through WNY and statewide collaborative opportunities
  - Structure an innovative cancer program to deliver transformational science, including Immunotherapy and personalized medicine
- Implementation of strategic research initiatives
- Expand capabilities for commercializing Roswell Park innovations
- Significant capital investment to upgrade existing IT systems, expand capacity and maintain currency for clinical technology

203.6(d)

- Labor/Workforce Instability
  - Recruitment and retention
  - Rising employment costs
- Durable/Sustained Inflation
- Ongoing Pandemic costs/impacts
- Drug Reimbursement
- Continued Uncertainty of Federal Budget
  - NCI Funding
  - Medicare & Medicaid reimbursement
  - DSH funding
- Managed Care
  - Increasing role of national insurance companies for commercial and Medicare Advantage plans
  - Increasing use of limited and tiered networks and ACO's
  - Benefit designs continue to require higher cost share (copays/coinsurance/deductible) for patients for certain services

### Budgeted Revenues, Expenditures and Changes in Current Net Assets (in 000's)

203.6(e)/203.6(g)

REVENUE & FUNDING SOURCES	 Last Year (Actual) FY22	urrent Year Estimated) FY23	Proposed Budget FY24	ı	Proposed FY25	ı	Proposed FY26	Proposed FY27
Operating Revenues								
Charges for Services	\$ 903,543	\$ 977,878	\$ 1,118,800	\$	1,206,072	\$	1,339,067	\$ 1,422,002
Other Operating revenues	25,101	28,091	33,494		34,252		35,269	35,867
Non-operating Revenues								
Investment earnings	(1,222)	222	13,679		15,411		13,237	12,844
State subsidies/grants	102,767	112,767	112,767		112,767		112,767	112,767
Federal subsidies/grants	2,770	3,534	_		_		_	_
Total Revenues and Funding Sources	\$ 1,032,958	\$ 1,122,492	\$ 1,278,740	\$	1,368,502	\$	1,500,340	\$ 1,583,480
<u>EXPENDITURES</u>								
Operating expenditures								
Salaries and Wages	\$ 347,751	\$ 377,457	\$ 437,641	\$	470,079	\$	499,008	\$ 522,555
Other Employee Benefits	102,119	101,435	116,630		128,567		137,836	146,765
Professional Services and Contracts	114,429	137,871	155,313		164,315		166,562	171,058
Supplies and Materials	367,903	430,275	481,353		529,210		581,462	617,485
Other operating expenditures	11,267	12,230	10,691		11,472		11,989	12,415
Non-operating expenditures  Payment of principal on bonds and financing								
arrangements	19,084	15,758	16,804		14,662		13,395	1,595
Interest and other fiscal charges on debt	1,550	1,923	3,287		2,917		2,258	2,036
Capital asset outlay	38,234	67,005	93,628		73,342		51,494	50,723
Miscellaneous	· —	, <u> </u>	· —		· —		· —	, <u> </u>
Total Expenditures	\$ 1,002,338	\$ 1,143,954	\$ 1,315,347	\$	1,394,564	\$	1,464,004	\$ 1,524,632
Capital Contributions	3,526	16,987	25,383		18,529		2,000	_
"Excess (deficiency) of revenues and capital contributions over expenditures"	\$ 34,146	\$ (4,475)	\$ (11,224)	\$	(7,533)	\$	38,336	\$ 58,848

### Cash Flow Projections (in millions)

203.5(h)

	Pro	jected	Budgeted	Budgeted	Budgeted	Budgeted
	F	Y23	FY24	FY25	FY26	FY27
Excess/(Deficiency) of revenues and capital contributions over expenditures	\$	(4.5)	\$ (11.2)	\$ (7.5)	\$ 38.3	\$ 58.8
Other Changes in Unrestricted Cash		(2.8)	(31.1)	(22.8)	(25.3)	(7.3)
Cash Impact from Operations	\$	(7.3)	\$ (42.4)	\$ (30.3)	\$ 13.1	\$ 51.5

### Projected Operating Revenues -- Net Patient Service Revenue (Charges for Services) (in 000's)

203.5(d)

	'	FY23	FY24	FY25	FY26	FY27
		Projected	Budget	Budget	Budget	Budget
Volume Statistics						
Admits		5,286	5,673	5,968	6,220	6,285
Days		43,206	48,397	50,650	52,423	52,922
Visits		299,746	320,123	336,963	351,731	355,567
Direct Patient Service Revenue						
RPCI IP Revenue	\$	242,516 \$	296,313	\$ 322,521 \$	342,949 \$	358,129
RPCI OP Revenue		598,527	682,503	739,840	845,533	908,517
Other		59,328	63,729	65,759	67,954	70,147
RPCI Total	\$	900,371 \$	1,042,545	\$ 1,128,120 \$	1,256,436 \$	1,336,793
CPP IP Revenue	\$	131,964 \$	24,354	\$ (77,723) \$	(80,055) \$	(80,055)
CPP OP Revenue		(51,004)	65,177	173,994	182,583	186,151
CPP Total	\$	80,960 \$	89,531	\$ 96,271 \$	102,528 \$	106,096
Total Direct Patient Service Revenue	\$	981,331 \$	1,132,076	\$ 1,224,391 \$	1,358,964 \$	1,442,889
Other RPCI Patient Service Revenue	\$	8,459 \$	1,339	\$ (2,327) \$	(2,437) \$	(2,550)
Other CPP Patient Service Revenue		700	700	700	700	700
Total Other Patient Service Revenue	\$	9,159 \$	2,039	\$ (1,627) \$	(1,737) \$	(1,850)
Total Net Patient Service Revenue	\$	990,490 \$	1,134,115	\$ 1,222,764 \$	1,357,227 \$	1,441,039
RPCI Provision for Bad Debts	\$	13,542 \$	16,263	\$ 17,667 \$	19,171 \$	20,114
CPP Provision for Bad Debts		769	851	915	974	1,008
Total Provision for Bad Debts	\$	14,311 \$	17,114	\$ 18,582 \$	20,145 \$	21,122
Total Net Patient Service Revenue Net of Provision for Bad Debt	\$	976,179 \$	1,117,001	\$ 1,204,182 \$	1,337,082 \$	1,419,917
Grants and Contracts		1,700	1,800	1,890	1,985	2,084
Total Charges for Services	\$	977,878 \$	1,118,800	\$ 1,206,072 \$	1,339,067 \$	1,422,002

### Projected Operating Revenues — Other Operating Revenue (in 000's)

203.5(d)

	FY23		FY24	FY25	FY26	FY27
(in thousands)		Projected	Budget	Budget	Budget	Budget
Cafeteria	\$	1,540 \$	1,571 \$	1,587 \$	1,603 \$	1,619
Parking		2,819	2,833	2,861	2,890	2,918
Rebates (VHA)		2,435	2,460	2,485	2,509	2,535
Other Operating Revenues (PC's/JV's)		6,397	11,672	11,813	11,955	12,099
Network Affiliations, Agreements & Partnerships		6,270	7,165	7,259	7,353	7,449
LSB - UB Reimbursement		1,350	1,350	1,364	1,377	1,391
New Programs funded through Alliance		3,612	3,330	3,808	4,443	4,652
WNY Partnership/Rest of NY Initiatives		1,300	1,300	1,316	1,332	1,348
All Other		2,367	1,813	1,760	1,807	1,856
Projected Operating Revenues	\$	28,091 \$	33,494 \$	34,252 \$	35,269 \$	35,867

### Salary & Fringe and Non Personnel Service Operating Expense (in 000's)

203.5(e)/203.5(f)

	FY23 Projected	FY24 Budget	FY25 Budget	FY26 Budget	FY27 Budget
<u>Salaries</u>					
Salaries and Wage Costs	\$ 377,457 \$	437,641 \$	470,079 \$	499,008 \$	522,555
TOTAL Personnel Service Expense	\$ 377,457 \$	437,641 \$	470,079 \$	499,008 \$	522,555
					_
<u>Fringe</u>					
NYS Pension Expense & TIAA CREF	\$ 25,923 \$	30,679 \$	36,152 \$	38,723 \$	41,302
Health Insurance: Active	30,445	33,841	36,549	39,473	42,630
Health Insurance: OPEB Payments	11,609	12,499	13,534	14,714	15,712
Other Fringe	33,458	39,610	42,332	44,926	47,121
TOTAL Fringe Expense	\$ 101,435 \$	116,630 \$	128,567 \$	137,836 \$	146,765

Note: The fringe expense includes the cash payments for NYS Pension & OPEB, but does not include the accrued cost.

#### Non Personnel Service Operating Expense

Professional Services & Contracts	\$ 137,871	\$ 155,313	\$ 164,315 \$	166,562 \$	171,058
Pharmaceuticals	\$ 352,160	\$ 394,115	\$ 429,509 \$	470,049 \$	500,225
Medical, Blood, Other Supplies	78,115	87,238	99,701	111,413	117,260
Supplies & Materials	\$ 430,275	\$ 481,353	\$ 529,210 \$	581,462 \$	617,485
Other Operating Expenditures	\$ 12,230	\$ 10,691	\$ 11,472 \$	11,989 \$	12,415
TOTAL Non Personnel Service Expense	\$ 580,376	\$ 647,357	\$ 704,997 \$	760,013 \$	800,958

## Reconciliation FY23 Amended Budget to FY23 Projected (in millions)

203.6(f)

	(in	millions)
1 Excess (Deficiency) Revenues over Expenses (FY23 Amended Budget)	\$	(31.1)
2 Clinical Margin (volume driven)		6.0
3 Compensation Adjustments		(3.2)
4 Increased Utility Costs		(2.6)
5 Third Party Revenue (Medicare ICR Settlement/HCRA)		6.2
6 Timing of Capital & Strategic Investments		19.4
7 All Other		0.8
8 Excess (Deficiency) Revenues over Expenses (FY23 Projected)	\$	(4.5)

Functional Classification	Total # Employees	Total # Full Time	Total # FTE's
Clinical / Clinical Research / Academic	2,696	2,315	2,470
Scientific / Academic	185	160	170
Administrative and Other	878	760	807
Total All Functional Areas	3,759	3,236	3,447

#### **Sources of Funding:**

The Source of funding for the projected workforce is:

Patient Service Revenues - Government and Private Payers

**Grants and Contracts** 

**Donations** 

New York State Funding

As part of the Institute's long range strategic plan, investments are being made in clinical operations. These investments are critical to meeting the projected demand for oncology services and expanding access to Roswell Park's services.

#### **Revenue Enhancements and Cost Reduction Initiatives:**

Clinical Growth / Strategic Plan
Cost reduction efforts

(\$ in Millions) \$34.3M ongoing

#### FY2023 to FY2027 Material Non-Recurring Resources

203.6(j)

The Institute is projecting non-recurring capital contribution revenues of approximately \$17.0M in FY23, \$25.4M in FY24, \$18.5M in FY25, \$2M in FY26 and \$0.0M in FY27. These contributions are expected to assist in funding the continued growth at Roswell Park.

#### FY24 Material Shift in Resources Between Years

203.6(k)

Capital Projects and Strategic Investments can span multiple years. These projects are approved prior to initiation, and due to the magnitude of certain projects there can be an approved balance to carry forward to the next fiscal year. Carry over balances are determined and approved by executive leadership as part of the planning process for the next fiscal year.

203.5(g)/203.6(l)

PBC revenues are pledged to repayment of the following DASNY indebtedness issued through New York State Department of Health

	in Millions						
	Proposed						
	Budget	Projection	Projection	Projection			
<b>Borrowed Debt Outstanding</b>	FY24	FY25	FY26	FY27			
1 DASNY Debt issuance 7/13/2011				_			
2 DASNY Debt issuance 10/21/2016							
3 Capital lease obligations							
Debt outstanding at March 31st year end	<b>\$</b> 43.	3 \$ 29.0	\$ 15.8	\$ 14.3			

	111 000 5									
	Bonds	s	Capital Le	ases						
Scheduled Debt Service Payment	Principal	Interest	Principal	Interest						
For the Year ending March 31										
2023	\$ 14,286	\$2,915	\$38 \$	150						
2024	16,080	2,224	45	149						
2025	14,197	1,490	53	147						
2026	13,204	817	61	145						
2027	1,432	451	69	143						
2028-2032	5,472	1,286	490	671						
Thereafter	 4,614	367	3,679	1,133						
	 \$69,284	\$9,551	\$4,436 \$	2,539						

<sup>\*</sup>All debt is issued. There is currently no proposed debt.

in 000's

PBC revenues are pledged to repayment of the following DASNY indebtedness issued through New York State Department of Health:

On July 13, 2011, DASNY issued debt in the amount of \$48,180,000 (RPCI allocated 74.85%). Under the terms of issuance interest ranges from 2.0% to 5.0% per annum with interest and principal payments due through 2037. The bond proceeds were used solely to defease a portion of the outstanding 1998 bond series.

On October 21, 2016, DASNY issued debt in the amount of \$144,810,000 (RPCI allocated 80.76%). Under the terms of issuance interest ranges from 3.0% to 5.0% per annum with interest and principal payments due through 2037. The bond proceeds were used solely to defease a portion of the outstanding 2003, 2004-1, 2004-2 and 2005 bond series.

On June 1, 2012, RPCIC entered into a capital lease obligation to rent 226 parking spaces for a 35 year period. Under terms of the agreement, the cost of capital is estimated at 3.4% per annum with interest and principal payments due through 2047.

### Debt Service/Pledged Revenue and Debt Limited Levels (in 000's)

203.5(g)/203.6(l)

			Debt Service
	ebt Service	Pledged	Percent of
Debt Service as a percentage of Pledged Revenues*	FY24	Revenues	Pledged Revenues
1 DASNY Debt issuance 7/13/11	\$ 2,384 \$	981,307	0.2%
2 DASNY Debt issuance 10/21/16	\$ 15,921 \$	981,307	1.6%
Total	\$ 18,304	_	1.9%

<sup>\*</sup>Pledged revenues are defined in accordance with RPCI bond documents

### Capital Summary (in 000's)

Facilities and Infrastructure
Clinical, Scientific & Administrative Equipment
Information Technology (including Rev Cycle)
Total Capital Expenditures

FY24	
Budget	
\$	53,155
	12,368
	28,105
\$	93,628

#### **CERTIFICATION**

By checking this box, I certify that the OSC Budget Request (Part 203) submission is complete and to the best of my knowledge and belief after reasonable inquiry, the information provided in this submission is accurate and correct. This information has been presented to and accepted by the authority's board.

\_\_\_\_\_

Chief Financial Officer
Roswell Park Cancer Institute Corporation

Presented to The Roswell Park Board of Directors on March 29, 2023 Approved by the Board of Director's on March 29, 2023